Uzma Syed, DO
Infectious Disease · Bay Shore, NYNPI 1730496449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 78.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $229, more than ten times the $13 reported in 2020.
Across 15 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$221
- Merck$60
Across 25 payments — averaging $10,668 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$267K
What the payments were for
- Food & beverage$281100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$281 in reported general payments places this provider in the 55th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 15 | $28,686 |
| ErtapenemErtapenem Sodium | 26 | $13,444 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 29 | $6,310 |
| Vancomycin Hcl | 23 | $3,025 |
| Cefazolin Sodium | 26 | $2,214 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bay Shore
- Lenny WeinsteinBay Shore$97K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
- Stephen ThomasSyracuse$294K
- Glenn TurettFlushing$253K
- Genovefa PapanicolaouNew York$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.